Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279506 | 0.83 | PPARD (0.41) | PPARDPTGDR2PTGER1THRATHRB | |
| SCHEMBL2275741 | 0.83 | PPARD (0.37) | PPARDPTGDR2PTGER1THRATHRB | |
| SCHEMBL2281950 | 0.83 | PTGDR2 (0.43) | PPARDPTGDR2THRATHRBFFAR1 | |
| SCHEMBL2275762 | 0.80 | PPARD (0.41) | PPARDPTGDR2PTGER1THRATHRB | |
| Benzene SCHEMBL2281937 | 0.80 | PPARD (0.44) | PPARDPTGDR2THRATHRBFFAR1 | |
| SCHEMBL2282375 | 0.80 | PPARD (0.43) | PPARDPTGDR2THRATHRBFFAR1 | |
| SCHEMBL2281925 | 0.80 | PTGDR2 (0.44) | PPARDPTGDR2THRATHRBFFAR1 | |
| SCHEMBL2282723 | 0.79 | PTGDR2 (0.41) | PPARDPTGDR2SCN9ATHRATHRB | |
| SCHEMBL2279344 | 0.78 | PTGDR2 (0.43) | PPARDPTGDR2THRATHRBFFAR1 | |
| SCHEMBL2279933 | 0.78 | PPARD (0.39) | PPARDPTGDR2THRATHRBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PPARD 27/4885PTGDR2 2/4885PTGER1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.